Global Newsroom

CSL continues to provide medicines to patients around the world.

Development of the University of Queensland’s vaccine candidate remains CSL’s priority.

The report made by the Courier Mail and other media agencies today that an agreement has been struck to specifically secure supply, when a vaccine is available, for Queensland, is incorrect.

Economist Intelligence Unit (EIU) Report launched today reveals only one in three rare disease patients receives the best-available, evidence-based care.

Less than a third of surveyed healthcare professionals (HCPs) in Australia encounter a rare disease patient more than once every six months.

Across APAC, 94% of rare conditions have no approved medical treatment, highlighting need to shift towards the provision of non-medical services.

Here is how CSL is working around the world with academia, industry and governments to combat the novel coronavirus COVID-19

Today, the first human trials using the University of Queensland’s (UQ) COVID-19 vaccine have commenced in Australia

Phase II placebo-controlled study will assess the safety and efficacy of CSL312 for the treatment of patients with severe respiratory distress due to COVID-19 related pneumonia.

CSL Behring now evaluating 5 approaches to preventing and treating COVID-19.

Unique gene therapy has the potential to be one of the first to market treatments to provide potentially long-term benefits with only one dose.

CSL Behring builds on legacy of delivering innovative treatment options for people with Hemophilia B.

Investigational Monoclonal Antibody Granted U.S. FDA Orphan Drug Designation

Builds on CSL Behring’s promise and commitment to the transplant community.

Deal accelerates the addition of clazakizumab, an anti-IL6 MAB currently in phase III development for treatment of chronic active antibody-mediated rejection, into CSL Behring’s portfolio.

• CSL appointed Trusted Manufacturer for University of Queensland’s “molecular clamp” enabled COVID-19 vaccine candidate
• CEPI and CSL will share costs associated with the clinical development and manufacture of the vaccine candidate
• A vaccine is anticipated to be available in 2021 if clinical trials are successful

Applications are now open for the 2021 CSL Centenary Fellowships, which are offered to outstanding mid-career scientists seeking to undertake world-class medical research at an Australian academic institute.

Plasma-derived therapeutic with potential to treat serious complications of COVID-19.

King of Prussia, Pa. and Sioux Falls, S.D.

COVID-19 treatment candidate, a high-potency immunotherapy delivering human polyclonal antibodies targeted to SARS-CoV-2, generated from SAB’s novel platform technology, on-track for clinical evaluation as early as summer

Osaka, JAPAN, and King of Prussia, PA, USA

Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.

CSL Limited's statement on Coronavirus

Forbes Magazine named CSL among its Best Employers for Diversity 2020. The annual rankings, which measure diversity across six different categories, are based on an independent survey of more than 60,000 employees working in a range of industries.